Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $27.88, but opened at $27.18. Dianthus Therapeutics shares last traded at $27.79, with a volume of 13,869 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Oppenheimer initiated coverage on shares of Dianthus Therapeutics in a report on Thursday. They set an “outperform” rating and a $48.00 price objective for the company. Wedbush lowered their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Robert W. Baird initiated coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective on the stock. Finally, Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and an average price target of $45.13.

Dianthus Therapeutics Trading Down 1.9 %

The stock has a 50 day moving average price of $27.90 and a 200 day moving average price of $26.21. The company has a market cap of $805.92 million, a PE ratio of -4.71 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Dianthus Therapeutics in the first quarter worth $89,761,000. RA Capital Management L.P. bought a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $69,990,000. Great Point Partners LLC raised its holdings in shares of Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Octagon Capital Advisors LP lifted its position in Dianthus Therapeutics by 15.4% during the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after purchasing an additional 74,000 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.